Presentation on theme: "James L Kennedy MD, FRCPC I’Anson Professor of Psychiatry and Medical Science Head, Neurogenetics Section, Clarke Division, Director, Department of Neuroscience."— Presentation transcript:
James L Kennedy MD, FRCPC I’Anson Professor of Psychiatry and Medical Science Head, Neurogenetics Section, Clarke Division, Director, Department of Neuroscience Research Centre for Addiction and Mental Health (CAMH), University of Toronto & SG Potkin, D Mueller, M Masellis, N Potapova, F Macciardi Genetics and Neuroimaging: Current Findings and Future Strategies
Candidate gene selection for schizophrenia Neurotransmitter system genes –e.g. dopamine receptors, transporter Neurodevelopmental genes –Cortical development, patterning –Neuronal differentiation, migration –Synaptic protein genes Human post-mortem expression studies (Mirnics et al, 2000; Vawter et al, 2001) Animal model expression studies (Wong et al, 2002; Barrett et al, 2003) Dissect the neurotransmitter, synaptic machinery, myelin system, etc, with molecular genetics… Neuroimaging will help both hypothesis generation and validation of new genetic findings
Cytoarchitectural abnormalities Control Schizophrenia Comparison of hippocampal pyramids at the CA1 and CA2 interface between control and schizophrenic. Cresyl violet stain, original magnification X250 Conrad et al. (1991) Arch Gen Psychiatry
Symptoms of TD TD is characterized by abnormal involuntary movements of the lip, jaw and tongue. Choreoathetoid movements of the extremities and/or trunk may occur as well. - Symptoms are measured using scales such as : the Abnormal Involuntary Movement Scale (AIMS) and the Rockland Simpson Scale (RSS). - The AIMS scale ranges from 0 - 40 and patients with higher AIMS scores have more severe symptoms.
Why DRD3 ? D3 mRNA and protein have been localized to the ventral side of the striatum and the ventral putamen (motor control) (Joyce & MeadorWoodruff, 1997) D3 receptors have been shown to have an inhibitory effect on locomotor activity in rats. (Kling-Peterson et al, 1995) Evidence that the Msc I polymorphism of DRD3 is functional: allelic differences display different affinities for dopamine in vitro. (Lundstrom & Turpin, 1996)
Mean AIMS Scores for DRD3 Msc I Polymorphism after Typical Neuroleptic Treatment Corrected Mean AIMS score DRD3 Genotype F[2,95] = 8.25, p < 0.0005 ( n = 112 ), Power = 0.568, r-square=0.297 (Bonferroni p < 0.0015) (Basile et al, 1999) n=34n=53n=25 Mean 14.20 Mean 3.920 Mean 3.470
Ethnically Stratified Means 33 43 9 9 16 F[2,83]=3.85, p = 0.026 (Bonferroni p = 0.078) F[1,23]=8.10, p = 0.0091 (Bonferroni p = 0.009)
CYP2D6 vs 1A2 (12.7%) (1.5%) (Shimoda et al, 1994) - Metabolism is determined by both affinity and abundance relative to the total liver P450 content. - 2D6 has a higher affinity for most typicals, but it accounts for only 2% of total liver content. 2D6 is “high affinity-low capacity” -2D6 is not inducible; 1A2 is Note: CYP2D6 also expressed in brain – neuroimaging may capture some of this variance
Mean AIMS Scale Scores for DRD3 by CYP1A2 Genotype DRD3 Genotype CYP1A2 Genotype Mean AIMS Score Additive recessive model strongly supported compared to alternative models
Tardive Dyskinesia Summary : - Given the numerous replications of the DRD3-TD finding, and the PET neuroimaging validation, it appears that the dopamine D3 receptor is involved in TD susceptibility. - The interaction between DRD3 and CYP1A2 genes fits a recessive - recessive model with each gene interacting additively. - The DRD3 and CYP1A2 results account for ~55% of the variance in TD; other genes and environment may account for the rest. ??Clinical genetic test for TD risk in the future??
Clozapine Response Prediction Algorithm? Arranz et al (2000) have reported a multi-gene (n = 10+ markers) model for clozapine response in one sample. Includes: D2, D4; 5HT1A, 2A, 2C, 4, 6; H1, H3,… Model must be replicated in a new sample to be meaningful Neuroimaging as a augmenting phenotype in each patient may provide valuable intermediary information from the brain, allowing more biologically meaningful subtyping.
5HTT specific ligand in PET 5HTT specific ligand for PET [ 11 C]DASB optimized in Toronto by radiochemist Alan Wilson N = 20 medication-free depressed patients, 20 anxiety disorder, and 20 normal controls underwent PET imaging with [ 11 C]DASB ligand; blood for genetics 5HTT gene typed for ins/del in promoter and the VNTR in intron II
[ 11 C] DASB Binding to 5HTT in Depressives vs Normals by Genotype: Frontal Region nM
PET Ligand (DASB) 5HTT Binding Potential correlates with Dysfunctional Attitude Serotonin Transporter Ligand Binding Potential Dysfunctional Attitude Scale Score [Meyer et al, Toronto PET Group, Arch Gen Psych, 2004] 5HTTLPR genetic marker does not predict 5HTT Binding (Kennedy et al, in prep) N=20 Major Depressives P <.001
Will the Brain Derived Neurotrophic Factor (BDNF) Gene Predict Grey Matter Volume? Val-66-met (GT)n repeat (function? mRNA stability) Exon 11 BDNF-1 SNP BDNF-2 BDNF-3BDNF-4
BDNF val66met: MRI functional brain imaging (Egan et al, Cell 2003) The red/yellow areas indicate brain regions (primarily hippocampus) that function differently between val/val (n=8) and val/met (n=5) subjects while performing a working memory task. Subjects with the met allele had more abnormal function.
Haplotype TDT: BDNF (GT)n repeat & val66met in schizophrenia * * HTDT for 170-val 66 2 = 7.11; 1 df; p = 0.007 Muglia et al, (2002)
Neurotrophic Mechanisms in Depression Nestler et al, 2002
Bipolar Disorder: TDT studies show robust effect of BDNF gene Combined Toronto sample (Neves-Pereira et al, 2002; N=300) plus MIT (Sklar et al, 2003) (N=200 + 150 NIMH) for val66met yields p =.0000001 Phenotype dissection of our Toronto bipolar sample shows association with rapid cycling, non-suicidal, non-psychotic, earlier age at onset subjects (Mueller et al, in preparation)
BDNF polymorphisms in Childhood Onset Depression: Pittsburgh Sample N=104 pairs; 2 = 17.8; df=5; p= 0.0032 172 bp allele: OR = 0.55 168 bp allele: OR = 3.94 N=104 pairs; 2 =4.7;df=1; p=0.03 Haplotype p = 0.001 GT repeat alleles
Figure 1d: Principal deformation for the right hippocampus for normal controls (top) and schizophrenia patients (bottom). Four views (front, lateral, back, medial) of each shape are shown. The color indicates the direction and the magnitude of the deformation, changing from blue (inwards) to green (no deformation) to red (outwards). Hippocampal shape as a phenotype for genetic studies
Will MOG gene variants predict white matter abnormalities?
Figure 3:1-4: Statistical parametric maps of the fractional anisotropy (FA) (left) and Magnetic Transfer Ratio (MTR) (myelin) (right) group comparison. Similar areas in yellow on both maps correspond to the location of both the internal capsule and prefrontal white matter, and indicate smaller values of FA and myelin in schizophrenia patients (n=14) compared with controls (n=15). Prefrontal fMRI activity and myelin reduced in schizophrenia
UNC clustering Bundle selection Measurement along tract Fractional Anisotropy Hypothesis: MOG, MAG, MBP genes will predict quantity or distribution of myelinated tracts
Fornix Dorsal stream Corpus callosum Cingulum Frontal striatial projections DTI New MRI Imaging Technique Reveals Brain Circuits Actual white matter tracks in schizophrenic patient revealed by DTI (colors and location by J. Fallon)
Complexities in Genetics & Neuroimaging Genetic variants express themselves in many ways – singularly, or combined (haplotypes, epistasis, partial penetrance…) What are the appropriate phenotypes to use from brain imaging data? How to control massive multiple testing of genome scan x brain voxels (millions x millions)?
Summary D3 gene link to tardive dyskinesia validated by PET imaging D1 role in schizophrenia and clozapine response supported by genetic variants and PET activity pre/post clozapine BDNF gene candidate for grey matter measures? MOG gene candidate for white matter? Vast expanses of quality data await us: we only need to develop our informatics sophistication… National Alliance for Medical Imaging and Computing: NAMIC www.na-mic.org